Samyang Biopharm is headquartered in Seongnam, South Korea and was founded in 1995 as a business unit of public parent company, Samyang Holdings Corporation (founded in 1924), known worldwide for their pharmaceuticals, chemicals and food businesses. Samyang Holdings is on the Korea Exchange KRX and 2017 annual sales revenues were ~$3.4 B.
Samyang Biopharm’s R&D Center is located in Pankyo and Manufacturing facilities are in Daejon. The current pipeline consists of 4 distinct areas: Medical Device, Polymer based drug delivery system, API’s, Biologics and three proprietary platforms: Polymeric Micelle, (PM); PolymericNano Particle, (PNP); and the Stability Enhanced Nano Shell, (SENS).
Samyang Biopharm has several marketed and pipeline products within generic oncology injectables, transdermal patches, API’s and medical devices in Asia. Samyang Biopharm continually focuses on developing innovative product. Genexol® PM and Nanoxel® M, which are anticancer drugs that applied the chemically synthesized nano-polymer DDS, are commercially available in South Korea.
They have also developed medical patches, such as a patch for cancer patients with severe-to-moderate pain, a smoking cessation patch, an anti-inflammatory analgesic patch, via the application of TDS (Transdermal Delivery System). In the field of API’s, Samyang has developed the plant cell culture method and succeeded in the world’s first mass production of paclitaxel as raw materials that are used in their oncology products.
Recently, Samyang has been focusing on developing treatment to maximize the effect of chemotherapy in combination with the anticancer drug in nano form and innovative technology that will deliver a nucleic acid-based agent such as siRNA, mRNA, and pDNA. Such an innovative drug delivery system will open up new opportunities in the field of the monoclonal antibody, antibody-drug conjugate (ADC), and recombinant protein. Their future growth strategy also revolves around biologics drug development for the U.S. market, which will be headquartered at their first affiliate office in Boston, Massachusetts.